SALL1  expression in acute myeloid leukemia

Huda Salman; Xiao Shuai; Anh Thu Nguyen-Lefebvre; Banabihari Giri; Mingqiang Ren; Michael Rauchman; Lynn Robbins; Wei Hou; Hasan Korkaya; Yupo Ma

doi:10.18632/oncotarget.23448

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

SALL1 expression in acute myeloid leukemia

Huda Salman _, Xiao Shuai, Anh Thu Nguyen-Lefebvre, Banabihari Giri, Mingqiang Ren, Michael Rauchman, Lynn Robbins, Wei Hou, Hasan Korkaya and Yupo Ma

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2018; 9:7442-7452. https://doi.org/10.18632/oncotarget.23448

Metrics: PDF 2283 views | HTML 2689 views | ?

Abstract

Huda Salman1,2, Xiao Shuai2,3,*, Anh Thu Nguyen-Lefebvre1,*, Banabihari Giri1, Mingqiang Ren1, Michael Rauchman4, Lynn Robbins4, Wei Hou2, Hasan Korkaya1 and Yupo Ma2

1Georgia Regent University Cancer Center, Augusta, GA, USA

2Present address: Stony Brook University Cancer Center, Stony Brook, NY, USA

3Department of Hematology, West China hospital of Sichuan University, Chengdu, P.R. China

4Department of Nephrology, Saint Louis University, St Louis, MO, USA

*These authors contributed equally to this work

Correspondence to:

Huda Salman, email: [email protected]

Keywords: SALL1; AML

Received: August 18, 2017 Accepted: October 25, 2017 Published: December 15, 2017

ABSTRACT

Similar signaling pathways could operate in both normal hematopoietic stem and progenitor cells (HSPCs) and leukemia stem cells (LSCs). Thus, targeting LSCs signaling without substantial toxicities to normal HSPCs remains challenging. SALL1, is a member of the transcriptional network that regulates stem cell pluripotency, and lacks significant expression in most adult tissues, including normal bone marrow (NBM). We examined the expression and functional characterization of SALL1 in NBM and in acute myeloid leukemia (AML) using in vitro and in vivo assays. We showed that SALL1 is expressed preferentially in LSCs- enriched CD34+CD38- cell subpopulation but not in NBM. SALL1 inhibition resulted in decreased cellular proliferation and in inferior AML engraftment in NSG mice and it was also associated with upregulation of PTEN and downregulation of m-TOR, β-catenin, and NF- қB expression. These findings suggest that SALL1 inhibition interrupts leukemogenesis. Further studies to validate SALL1 as a potential biomarker for minimal residual disease (MRD) and to determine SALL1’s role in prognostication are ongoing. Additionally, pre-clinical evaluation of SALL1 as a therapeutic target in AML is warranted.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23448

Publication Alerts

Research Papers:

SALL1 expression in acute myeloid leukemia

Abstract